Loading…
Thrombosis and Coagulopathy in COVID-19
Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on March 11, 2020, the World Health Organization declared the new Coronavirus disease 2019 (COVID-19) as a pandem...
Saved in:
Published in: | Current problems in cardiology 2021-03, Vol.46 (3), p.100742-100742, Article 100742 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c475t-d803ed67a0f0538b3647e9f671fc981262965ca1467f18242331c0fbcc1ceef23 |
---|---|
cites | cdi_FETCH-LOGICAL-c475t-d803ed67a0f0538b3647e9f671fc981262965ca1467f18242331c0fbcc1ceef23 |
container_end_page | 100742 |
container_issue | 3 |
container_start_page | 100742 |
container_title | Current problems in cardiology |
container_volume | 46 |
creator | Gómez-Mesa, Juan Esteban Galindo-Coral, Stephania Montes, Maria Claudia Muñoz Martin, Andrés J. |
description | Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on March 11, 2020, the World Health Organization declared the new Coronavirus disease 2019 (COVID-19) as a pandemic. The presence of comorbidities (eg, cardiovascular disease, obesity), Sepsis Induced Coagulopathy score >4, elevation of D-dimer (>6 times the normal value), C-reactive protein, troponins and other disseminated intravascular coagulation markers; is associated to a worse prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42%. Initial anticoagulant treatment with low molecular weight heparin has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure/inspired fraction of O2 (PaO2/FiO2) by mitigating the formation of microthrombi and associated pulmonary coagulopathy. |
doi_str_mv | 10.1016/j.cpcardiol.2020.100742 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7605852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0146280620302188</els_id><sourcerecordid>2465438875</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-d803ed67a0f0538b3647e9f671fc981262965ca1467f18242331c0fbcc1ceef23</originalsourceid><addsrcrecordid>eNqFkE1PAjEQhhujEUT_gnLTy2K_272YkPWLhIQLem1KtwslyxbbhYR_724WiZ48zWTmnfedPADcIThCEPHH9chsjQ658-UIQ9xOoaD4DPQRIyzhWMJz0IeI8qRpeQ9cxbiGEOEU8UvQIwRTQinsg_v5KvjNwkcXh7rKh5nXy13pt7peHYauGmazz8lzgtJrcFHoMtqbYx2Aj9eXefaeTGdvk2w8TQwVrE5yCYnNudCwgIzIBeFU2LTgAhUmlQhznHJmdPOXKJDEFBOCDCwWxiBjbYHJADx1vtvdYmNzY6s66FJtg9vocFBeO_V3U7mVWvq9EhwyyVqDh6NB8F87G2u1cdHYstSV9buoMOWMEikFa6Sik5rgYwy2OMUgqFrMaq1OmFWLWXWYm8vb31-e7n64NoJxJ7ANq72zQUXjbGVs7oI1tcq9-zfkG0c4kOU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2465438875</pqid></control><display><type>article</type><title>Thrombosis and Coagulopathy in COVID-19</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Gómez-Mesa, Juan Esteban ; Galindo-Coral, Stephania ; Montes, Maria Claudia ; Muñoz Martin, Andrés J.</creator><creatorcontrib>Gómez-Mesa, Juan Esteban ; Galindo-Coral, Stephania ; Montes, Maria Claudia ; Muñoz Martin, Andrés J.</creatorcontrib><description>Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on March 11, 2020, the World Health Organization declared the new Coronavirus disease 2019 (COVID-19) as a pandemic. The presence of comorbidities (eg, cardiovascular disease, obesity), Sepsis Induced Coagulopathy score >4, elevation of D-dimer (>6 times the normal value), C-reactive protein, troponins and other disseminated intravascular coagulation markers; is associated to a worse prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42%. Initial anticoagulant treatment with low molecular weight heparin has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure/inspired fraction of O2 (PaO2/FiO2) by mitigating the formation of microthrombi and associated pulmonary coagulopathy.</description><identifier>ISSN: 0146-2806</identifier><identifier>EISSN: 1535-6280</identifier><identifier>DOI: 10.1016/j.cpcardiol.2020.100742</identifier><identifier>PMID: 33243440</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Blood Coagulation Disorders - epidemiology ; Blood Coagulation Disorders - etiology ; COVID-19 - complications ; COVID-19 - epidemiology ; Global Health ; Humans ; Incidence ; Pandemics ; SARS-CoV-2 ; Thrombosis - epidemiology ; Thrombosis - etiology</subject><ispartof>Current problems in cardiology, 2021-03, Vol.46 (3), p.100742-100742, Article 100742</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-d803ed67a0f0538b3647e9f671fc981262965ca1467f18242331c0fbcc1ceef23</citedby><cites>FETCH-LOGICAL-c475t-d803ed67a0f0538b3647e9f671fc981262965ca1467f18242331c0fbcc1ceef23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33243440$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gómez-Mesa, Juan Esteban</creatorcontrib><creatorcontrib>Galindo-Coral, Stephania</creatorcontrib><creatorcontrib>Montes, Maria Claudia</creatorcontrib><creatorcontrib>Muñoz Martin, Andrés J.</creatorcontrib><title>Thrombosis and Coagulopathy in COVID-19</title><title>Current problems in cardiology</title><addtitle>Curr Probl Cardiol</addtitle><description>Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on March 11, 2020, the World Health Organization declared the new Coronavirus disease 2019 (COVID-19) as a pandemic. The presence of comorbidities (eg, cardiovascular disease, obesity), Sepsis Induced Coagulopathy score >4, elevation of D-dimer (>6 times the normal value), C-reactive protein, troponins and other disseminated intravascular coagulation markers; is associated to a worse prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42%. Initial anticoagulant treatment with low molecular weight heparin has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure/inspired fraction of O2 (PaO2/FiO2) by mitigating the formation of microthrombi and associated pulmonary coagulopathy.</description><subject>Blood Coagulation Disorders - epidemiology</subject><subject>Blood Coagulation Disorders - etiology</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - epidemiology</subject><subject>Global Health</subject><subject>Humans</subject><subject>Incidence</subject><subject>Pandemics</subject><subject>SARS-CoV-2</subject><subject>Thrombosis - epidemiology</subject><subject>Thrombosis - etiology</subject><issn>0146-2806</issn><issn>1535-6280</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkE1PAjEQhhujEUT_gnLTy2K_272YkPWLhIQLem1KtwslyxbbhYR_724WiZ48zWTmnfedPADcIThCEPHH9chsjQ658-UIQ9xOoaD4DPQRIyzhWMJz0IeI8qRpeQ9cxbiGEOEU8UvQIwRTQinsg_v5KvjNwkcXh7rKh5nXy13pt7peHYauGmazz8lzgtJrcFHoMtqbYx2Aj9eXefaeTGdvk2w8TQwVrE5yCYnNudCwgIzIBeFU2LTgAhUmlQhznHJmdPOXKJDEFBOCDCwWxiBjbYHJADx1vtvdYmNzY6s66FJtg9vocFBeO_V3U7mVWvq9EhwyyVqDh6NB8F87G2u1cdHYstSV9buoMOWMEikFa6Sik5rgYwy2OMUgqFrMaq1OmFWLWXWYm8vb31-e7n64NoJxJ7ANq72zQUXjbGVs7oI1tcq9-zfkG0c4kOU</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Gómez-Mesa, Juan Esteban</creator><creator>Galindo-Coral, Stephania</creator><creator>Montes, Maria Claudia</creator><creator>Muñoz Martin, Andrés J.</creator><general>Elsevier Inc</general><general>Mosby-Year Book</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210301</creationdate><title>Thrombosis and Coagulopathy in COVID-19</title><author>Gómez-Mesa, Juan Esteban ; Galindo-Coral, Stephania ; Montes, Maria Claudia ; Muñoz Martin, Andrés J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-d803ed67a0f0538b3647e9f671fc981262965ca1467f18242331c0fbcc1ceef23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Blood Coagulation Disorders - epidemiology</topic><topic>Blood Coagulation Disorders - etiology</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - epidemiology</topic><topic>Global Health</topic><topic>Humans</topic><topic>Incidence</topic><topic>Pandemics</topic><topic>SARS-CoV-2</topic><topic>Thrombosis - epidemiology</topic><topic>Thrombosis - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gómez-Mesa, Juan Esteban</creatorcontrib><creatorcontrib>Galindo-Coral, Stephania</creatorcontrib><creatorcontrib>Montes, Maria Claudia</creatorcontrib><creatorcontrib>Muñoz Martin, Andrés J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current problems in cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gómez-Mesa, Juan Esteban</au><au>Galindo-Coral, Stephania</au><au>Montes, Maria Claudia</au><au>Muñoz Martin, Andrés J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thrombosis and Coagulopathy in COVID-19</atitle><jtitle>Current problems in cardiology</jtitle><addtitle>Curr Probl Cardiol</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>46</volume><issue>3</issue><spage>100742</spage><epage>100742</epage><pages>100742-100742</pages><artnum>100742</artnum><issn>0146-2806</issn><eissn>1535-6280</eissn><abstract>Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on March 11, 2020, the World Health Organization declared the new Coronavirus disease 2019 (COVID-19) as a pandemic. The presence of comorbidities (eg, cardiovascular disease, obesity), Sepsis Induced Coagulopathy score >4, elevation of D-dimer (>6 times the normal value), C-reactive protein, troponins and other disseminated intravascular coagulation markers; is associated to a worse prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42%. Initial anticoagulant treatment with low molecular weight heparin has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure/inspired fraction of O2 (PaO2/FiO2) by mitigating the formation of microthrombi and associated pulmonary coagulopathy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33243440</pmid><doi>10.1016/j.cpcardiol.2020.100742</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0146-2806 |
ispartof | Current problems in cardiology, 2021-03, Vol.46 (3), p.100742-100742, Article 100742 |
issn | 0146-2806 1535-6280 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7605852 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Blood Coagulation Disorders - epidemiology Blood Coagulation Disorders - etiology COVID-19 - complications COVID-19 - epidemiology Global Health Humans Incidence Pandemics SARS-CoV-2 Thrombosis - epidemiology Thrombosis - etiology |
title | Thrombosis and Coagulopathy in COVID-19 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A00%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thrombosis%20and%20Coagulopathy%20in%20COVID-19&rft.jtitle=Current%20problems%20in%20cardiology&rft.au=G%C3%B3mez-Mesa,%20Juan%20Esteban&rft.date=2021-03-01&rft.volume=46&rft.issue=3&rft.spage=100742&rft.epage=100742&rft.pages=100742-100742&rft.artnum=100742&rft.issn=0146-2806&rft.eissn=1535-6280&rft_id=info:doi/10.1016/j.cpcardiol.2020.100742&rft_dat=%3Cproquest_pubme%3E2465438875%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-d803ed67a0f0538b3647e9f671fc981262965ca1467f18242331c0fbcc1ceef23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2465438875&rft_id=info:pmid/33243440&rfr_iscdi=true |